Melatonin Safety Profile

Evidence from Long-Term Studies

A 4-year follow-up study of children with delayed sleep-wake phase disorder and ADHD using doses up to 10 mg detected no serious adverse events, with 65% of participants continuing daily use throughout the study period 1
A prospective study extending up to 3.8 years in patients with neurodevelopmental disabilities receiving controlled-release melatonin (maximum 15 mg) similarly reported no adverse events 1
A 28-day toxicology trial in healthy male adults using 10 mg melatonin revealed no group differences in polysomnographic sleep parameters, clinical laboratory examinations, or subjective adverse events compared to placebo 1

Concerns about effects on growth hormone regulation and reproductive development appear unfounded based on available evidence, with a questionnaire-based study following children/adolescents for approximately 3 years (mean dose ~3 mg) finding no significant differences in pubertal development compared to non-melatonin users in the general population 1
Melatonin represents a safer alternative to traditional hypnotics in older adults, who face substantial risks from benzodiazepines and other sedative-hypnotics, with traditional hypnotics carrying increased risks for falls, confusion, impaired motor performance, anterograde amnesia, and physiologic dependence in elderly patients 1

The American Academy of Sleep Medicine identifies several situations requiring caution, including warfarin users, epilepsy patients, and those taking photosensitizing medications, with recommendations for monitoring and dose adjustments as needed 2
Higher doses may paradoxically increase adverse effects without improving efficacy, with lower doses recommended as starting points to minimize risk 2
The American Academy of Sleep Medicine recommends maximum doses of 5 mg for most indications, with morning grogginess and "hangover" effects more common with higher doses 3

The primary limitation in assessing long-term safety is the scarcity of studies extending beyond 6 months, with most controlled trials involving treatment durations of 4 weeks or less 1
The American Academy of Sleep Medicine recommends periodic reassessment of melatonin use due to limited long-term safety data 2

Product quality variability can be mitigated by choosing United States Pharmacopeial Convention Verified formulations for reliable dosing and purity, with timing errors and excessive dosing also potential pitfalls to avoid 2
Inadequate monitoring can lead to enhanced sedation, blood pressure changes, and mood alterations, with documentation of concurrent medications and regular monitoring recommended 2

The American Academy of Sleep Medicine reports that additional adverse effects of melatonin include trouble thinking, nausea, and hypothermia 4
Melatonin concentration of marketed preparations varies widely between product labels and manufacturers, but USP-verified products have been confirmed to contain the amounts stated on the label 4
Different formulations could potentially lead to varying efficacy between brands, highlighting the importance of choosing USP-verified products 4

The American Academy of Sleep Medicine suggests immediate-release melatonin as a treatment option for REM sleep behavior disorder, with studies demonstrating clinically significant improvements in dream-acting and vocalization episode frequency 4
The costs of medication are relatively small compared to the potential high cost of injury during sleep, making melatonin a viable treatment option for certain conditions 4